Table 1.
Advantages of using BMCT
| Advantages | Detail | References |
|---|---|---|
| Various administration routes | Intravenous | [4–18] |
| Intraperitoneal | [19–23] | |
| Intratumoral | [19, 24–27] | |
| Oral | [17, 28, 29] | |
| Broad tumor-targeting ability | Colon | [7, 9, 10, 14, 19, 24, 30, 31] |
| Fibrosarcoma | [17] | |
| Bladder | [13] | |
| Liver | [6, 7, 15, 30] | |
| Pancreas | [8, 21] | |
| Lung | [14, 15] | |
| Melanoma | [18, 20, 22, 27, 28, 31, 32] | |
| Breast | [4, 11, 12, 16, 23, 25, 31] | |
| Prostate | [20, 26] | |
| Flexibility of delivery | Protein derived from eukaryotes | [5, 12, 20, 29] |
| Protein derived from prokaryotes | [7, 11, 30, 31] | |
| Enzyme-prodrug | [4, 13] | |
| DNA | [18, 19, 25] | |
| siRNA, shRNA | [9, 26, 28] | |
| Facilitating host’s immune responses | TAM reduction | [16] |
| Antigen delivery | [17, 23, 33] | |
| Upregulation of gap junction | [27] | |
| Shift from immune suppressive to immunogenic | [22, 24] | |
| Noninvasive monitoring | Luminescence | [6, 7, 14, 30, 31, 34–37] |
| Fluorescence | [8] | |
| MRI | [38] | |
| PET | [39] | |
| Can be combined with other therapies | Chemotherapy | [5, 13, 15, 32] |
| Radiation | [12, 21, 31] | |
| Viral therapy | [14] |